Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

QIAGEN Achieves Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer

Published: Wednesday, July 11, 2012
Last Updated: Wednesday, July 11, 2012
Bookmark and Share
U.S. launch of therascreen® KRAS RGQ PCR kit offers enhanced approach to guide treatments for approximately 110,000 patients annually in U.S. with colorectal cancer.

QIAGEN N.V. has announced that it has received U.S. Food and Drug Administration (FDA) approval to market the therascreen® KRAS RGQ PCR Kit (therascreen KRAS test) to provide guidance on the use of Erbitux® (cetuximab) as a treatment in patients with metastatic colorectal cancer.

The U.S. FDA approval of the KRAS test kit marks a milestone in QIAGEN's global expansion of its Personalized Healthcare franchise which includes an industry-leading portfolio of molecular companion diagnostics to aid treatment decisions in oncology.

QIAGEN already markets a broad range of companion diagnostic tests covering 30 biomarkers in Europe, Asia/Pacific and Japan.

"We are very pleased to receive FDA approval to launch our therascreen KRAS test in the United States and to play a role in transforming the care of colorectal cancer patients. This approval marks an important step for QIAGEN, but also an important step in Personalized Healthcare, as we are now launching a major molecular companion diagnostic product in the U.S.," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.

Schatz continued, "With a growing portfolio of innovative tests and efficient automation platforms, we are proud to be helping to make healthcare more effective, providing ways for payers to more efficiently use healthcare resources and, most important, making a positive impact on the care of patients."

Pioneering role in Personalized Healthcare

QIAGEN is at the forefront of developing and validating a range of tests that provide physicians with an individual patient's molecular information to select the most appropriate medicines.

The entry into the U.S. market with the approval of the first therascreen test builds on our success in the European market, where QIAGEN offers 10 CE-marked assays, based either on real-time PCR technology or on Pyrosequencing.

QIAGEN currently markets therascreen assays in Europe for biomarkers including KRAS, EGFR, NRAS, BRAF, PI3K, JAK2, MGMT and UGT1A1.

In Japan, the therascreen KRAS and EGFR kits were approved in 2011, solidifying QIAGEN's leadership position for companion diagnostics in the second biggest market for Personalized Healthcare.

A range of assays and related Sample & Assay Technologies are also marketed to customers use during the research and development of new medicines.

QIAGEN is actively expanding its pipeline of Personalized Healthcare technologies and intends to submit several companion diagnostics in the coming years for U.S. regulatory approval.

QIAGEN has more than 15 projects under way to co-develop and market companion diagnostics with leading pharmaceutical and biotech companies such as Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, and Pfizer.

Benefiting patients and providers

Introduction of the therascreen KRAS test provides an FDA-approved diagnostic available for making treatment decisions for colorectal cancer patients.

Approximately 110,000 colorectal cancer patients each year in the U.S. could benefit from KRAS testing, according to QIAGEN estimates.

Studies show the U.S. healthcare system could save more than $600 million annually by avoiding unnecessary use of medicines in colorectal cancer patients through determinations of their KRAS status.

In metastatic colorectal cancer patients for whom standalone surgery and chemotherapy are insufficient, treatment with an epidermal growth factor receptor (EGFR) inhibitor has been shown to improve overall survival. However, the presence or absence of KRAS mutations in tumors affects outcomes: Approximately 60% of patients with mutation-negative (wild-type) KRAS genes may benefit from anti-EGFR therapy, while 40% whose tumors have KRAS mutations may not benefit.

The first FDA approval of the therascreen KRAS test pairs this companion diagnostic with Erbitux®, a leading EGFR inhibitor marketed in the U.S. by Bristol-Myers Squibb in partnership with Eli Lilly and its ImClone Systems unit.

According to the U.S. product information for Erbitux®, KRAS status evaluation using an FDA-approved diagnostic test is used to determine treatment, and the therascreen KRAS kit is currently the only test with this status.

Based on the FDA approval for use in metastatic colorectal cancer patients, the current annual U.S. market potential for sales of the therascreen KRAS kit in this indication only is approximately $20 million.

In contrast to laboratory-developed tests (LDTs), the FDA-approved therascreen KRAS test gives healthcare providers a fast, consistent and reliable process to determine optimal treatment for colorectal cancer patients who are candidates for EGFR-inhibitor therapy.

The therascreen KRAS kit has been shown to have higher sensitivity (i.e. a lower limit of detection, LOD) for KRAS mutations between 0.8% and 6.4% depending on the assay which is critical to ensuring reliable and consistent data for treatment decisions.

Following FDA approval, a number of laboratories will begin offering KRAS status evaluation with the therascreen KRAS test:

• Applied Diagnostics, Inc.
• Boyce & Bynum Pathology Laboratories
• Cellnetix Pathology & Laboratories
• Clinical Molecular Oncology Laboratory, The University of Kansas Medical Center
• Colorado Molecular Correlates Laboratory (CMOCO), University of Colorado
• Companion Dx Reference Lab, LLC
• Dahl-Chase Diagnostic Services
• Lab21 Inc.
• Mayo Clinic


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

QIAGEN,Biotype Diagnostics Form Partnership
New “Biotype Innovation” to develop workflows for personalized health-care and other applications based on QIAGEN’s ModaPlex platform.
Monday, June 29, 2015
Hitachi High-Technologies, QIAGEN Collaborate
Hitachi High-Technologies Corporation and QIAGEN N.V. have entered into a long-term strategic collaboration involving initiatives to deliver important advances in molecular testing.
Thursday, June 18, 2015
QIAGEN Expands Leadership in Liquid Biopsies
QIAGEN and Tokai Pharmaceuticals to co-develop and commercialize the first regulated CTC-based companion diagnostic to guide treatments in prostate cancer.
Tuesday, March 17, 2015
QIAGEN Collaborates with Allele Frequency Community
QIAGEN providing secure bioinformatics infrastructure and software for research and clinical labs to contribute and gain insights from Allele Frequency Community.
Wednesday, February 25, 2015
QIAGEN Signs Ninth Master Collaboration Agreement for Companion Diagnostics
Master collaboration agreement is a framework for developing and commercializing QIAGEN companion diagnostics, paired with new or existing products.
Thursday, November 13, 2014
QIAGEN, Astellas CDx Partnership
Collaboration provides options for collaboration across therapeutic areas, sample types and testing technologies.
Thursday, October 30, 2014
QIAGEN, BGI Tech Database Agreement
BGI Tech will provide services to the Greater China market with the widely used HGMD literature source.
Friday, August 01, 2014
QIAGEN, AstraZeneca to Develop Liquid Biopsy-based Companion Diagnostic
The collaboration is to advance EGFR mutation profiling in lung cancer patients.
Monday, July 28, 2014
QIAGEN Licenses Blood Cancer Biomarkers
Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including NGS gene panels, for blood cancers.
Saturday, July 26, 2014
QIAGEN Receives FDA Approval for CMV Assay
Assay offers faster quantification of CMV DNA levels in patient samples.
Friday, June 20, 2014
QIAGEN, Lilly form CDx Collaboration
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.
Friday, May 30, 2014
FDA Approve QIAGEN PCR Kit For Use With Second Colorectal Cancer Drug
Clinically proven companion diagnostic gains U.S. approval to guide use of Amgen’s Vectibix® (panitumumab) in treatment of metastatic colorectal cancer.
Tuesday, May 27, 2014
QIAGEN Integrates Content from BIOBASE
The new content expands the world’s most comprehensive, high-quality and up-to-date literature source for clinical research and diagnosis.
Wednesday, May 21, 2014
QIAGEN Receives FDA Clearance for QIAsymphony RGQ MDx
Clearance marks a milestone for one of the Company’s major global growth drivers.
Monday, May 05, 2014
QIAGEN Licences Biomarker for Blood Disorder from CeMM Vienna
Company plans to develop a molecular diagnostic test for the calreticulin mutations.
Thursday, April 10, 2014
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!